01—Abstract
Summary
Summary of the 10-Q filed May 1, 2024. Cited figures are marked; the original filing is the authoritative source.
Neurocrine Biosciences, Inc. reported first-quarter 2024 results in its Form 10-Q filed May 1, 2024, with net product sales of $509.0 milliona, up from $415.3 million in the prior-year quarter, driven primarily by INGREZZA net product sales of $506.0 million, which the filing attributes to strong underlying patient demand and improved gross-to-net dynamics.
Total revenues were $515.3 millionb versus $420.4 million, and the company posted net income of $43.4 million, or $0.42 per diluted share, compared with a net loss of $76.6 million in the first quarter of 2023. Results were affected by $88.7 million of charges tied to the bifurcation of the embedded conversion option of the 2.25% convertible senior notes due May 15, 2024, which the company elected to settle in cash. Acquired in-process R&D fell to $6.0 million from $143.9 million, and operating income was $99.3 million versus an operating loss of $114.2 million.
The balance sheet strengthened, with total cash, cash equivalents and marketable securities of $1.91 billionc at March 31, 2024, up from $1.72 billion at December 31, 2023, and operating cash flow of $130.3 million. The company stated that existing resources are sufficient for at least the next 12 months and that it has sufficient cash to repay the $170.4 million of remaining 2024 Notes at maturity. Business highlights for April 2024 included positive Phase 2 data for NBI-1065845 in major depressive disorder, two New Drug Applications submitted to the FDA for crinecerfont in classic congenital adrenal hyperplasia, and FDA approval of INGREZZA SPRINKLE.
The filing also notes that the company was notified by CMS in April 2024 that it qualified as a "specified small manufacturer" under the Medicare Part D manufacturer discount program, which will phase in the discount. The filing highlights concentration and reimbursement risks: four specialty pharmacy customers represented approximately 94% of total product sales in the quarter, and a majority of current revenue is derived from federal healthcare programs including Medicare and Medicaid. The company's potential future collaboration milestone payments total approximately $17.5 billiond across its existing agreements, and it reported 1,448 full-time employees as of March 31, 2024.
02—Key points
Key Highlights
- Net product sales rose to $509.0 million from $415.3 million, led by INGREZZA at $506.0 million, which the filing attributes to strong patient demand and improved gross-to-net dynamics.
- Net income was $43.4 million ($0.42 per diluted share) versus a net loss of $76.6 million a year earlier, though results include $88.7 million of charges from bifurcating the 2024 convertible notes' conversion feature.
- Operating income was $99.3 million compared with an operating loss of $114.2 million, as acquired IPR&D dropped to $6.0 million from $143.9 million.
- Total cash, cash equivalents and marketable securities reached $1.91 billion at March 31, 2024, up from $1.72 billion at December 31, 2023; operating cash flow was $130.3 million.
- The company elected to settle all conversions of its $170.4 million 2.25% convertible senior notes due May 15, 2024 in cash and states it has sufficient cash to repay them at maturity.
- April 2024 milestones included positive Phase 2 data for NBI-1065845 in major depressive disorder, two NDAs submitted for crinecerfont in classic CAH, and FDA approval of INGREZZA SPRINKLE.
- Four customers accounted for approximately 94% of total product sales in the quarter, and the company was notified by CMS in April 2024 that it qualified as a specified small manufacturer under the Medicare Part D discount program.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q1 FY2024, Neurocrine Biosciences kept $0.08.
- Revenue$515.3M100.0%
- Cost of revenue−$7.5M1.5%
- Gross profit$507.8M98.5%
- Operating costs−$408.5M79.3%
- Operating income$99.3M19.3%
- Interest, other & tax−$55.9M10.8%
- Net income$43.4M8.4%
04—Financials
Financial Highlights
Figures from 10-QQ1 FY2024filed May 1, 2024Financial Statements
Q1 FY2024 against Q1 FY2023
| Line item | Q1 FY2024Q1 FY2023 | Change |
|---|---|---|
| Revenue | $515.30M$420.40M | +22.6% |
| Cost of Revenue | $7.50M$8.50M | −11.8% |
| Gross Profit | $507.80M$411.90M | +23.3% |
| SG&A Expenses | $243.10M$242.70M | +0.2% |
| Operating Expenses | $416.00M$534.60M | −22.2% |
| Operating Income | $99.30M-$114.20M | +187.0% |
| Interest Expense | $1.10M$1.10M | 0.0% |
| Net Income | $43.40M-$76.60M | +156.7% |
| EPS (Basic) | $0.43$-0.79 | +154.4% |
| EPS (Diluted) | $0.42$-0.79 | +153.2% |
| Shares Outstanding (Basic) | 99.80M97.10M | +2.8% |
| Shares Outstanding (Diluted) | 103.60M97.10M | +6.7% |
05—Questions
Frequently Asked Questions
What drove the improvement in revenue and profitability this quarter?
The filing attributes the increase in net product sales primarily to higher INGREZZA net product sales, driven by strong underlying patient demand and improved gross-to-net dynamics. Operating income also improved because acquired in-process R&D expense fell to $6.0 million from $143.9 million in the prior-year quarter.
How did the convertible senior notes affect first-quarter results?
The company recorded $88.7 million of charges associated with its convertible senior notes, comprising $79.1 million of debt discount accretion and a $9.6 million change in fair value of the derivative liability. These charges arose after the company elected in January 2024 to settle conversions in cash, which required bifurcating the conversion feature.
Does the company have enough cash to meet its obligations?
The filing states that existing capital resources, anticipated INGREZZA net product sales and investment income are expected to be sufficient for at least the next 12 months. It also states the company has sufficient cash reserves to repay the $170.4 million of 2024 Notes at their May 15, 2024 maturity.
What are the main risks highlighted for investors?
The filing highlights reliance on INGREZZA for revenue, concentration among a few specialty pharmacy customers (about 94% of product sales in the quarter), and dependence on federal healthcare programs, with a majority of revenue derived from Medicare and Medicaid. It also cites exposure to drug pricing legislation including the Inflation Reduction Act and the new Part D manufacturer discount program.
What pipeline and regulatory developments were reported after the quarter ended?
In April 2024 the company reported positive Phase 2 results for NBI-1065845 in major depressive disorder, meeting its primary and key secondary endpoints. It also submitted two New Drug Applications to the FDA for crinecerfont in adult and pediatric classic congenital adrenal hyperplasia and received FDA approval for INGREZZA SPRINKLE.
06—Continue